Back to results
US 2020/0345712 A1Published application
Compositions and methods for treating cancer
AssigneeChildren's Hospital Medical Center
InventorsNicolas Nassar, William Seibel, Anjelika Gasilina, Jose Cancelas
Life of this patent
Estimating the term…
Abstract
A small molecule compound IODVA1 has been found to have cellular inhibitory activity against several transformed cell lines including Ras-driven cells. IODVA1 decreases cell-cell and cell-extra cellular matrix interactions and reduces growth of Ras-driven tumors. Applicants also synthesized compound NIRA2 and showed in vitro and in vivo efficacy and potency against models of Ph+(BCR-ABL1) B-ALL and of colon adenocarcinoma xenografts.
Claims18
A composition comprising
- and a pharmaceutically acceptable carrier;
- wherein A=NH, NR8, S, O, C═C, N═C, C═N
- wherein R1, R2 are independently substituted or unsubstituted* aryl or heteroaryl rings
- wherein R3=singly or multiply substituted as H, D, Halo, CN, C1-C4 Alkyl, C1-C4 alkoxy, C1-C4 alkylsulfonyl, C1-C4 Alkyl amino, or C1-C4 mercapto
- wherein R8=H, M;
- and all tautomers thereof.
3 more elements
A composition comprising
- wherein R1, R2, and R4 are independently selected from H, D, Halo, CN, OH, OMe, OEt, SMe, SEt, SO2Me, NHMe, NMe2, Me, Et, or Pr, and all tautomers thereof;
- wherein R3 is singly or multiply substituted as H, D, Halo, CN, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsufonyl;
- C1-C4 alkylamino, or C1-C4 mercapto;
- wherein A is selected from NH, NRB, S, O, C═C, N═C, C═N, wherein R8 is H or Me;
- wherein each Q is independently selected from N, C, and S;
- and a pharmaceutically acceptable carrier.
3 more elements
Dependencies are inferred from the claim text.